Kyung Sue Hong

Dr. Kyung Sue Hong


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
JKJun Soo Kwon
Jun Soo Kwon
YJYeon Ho Joo
Yeon Ho Joo
HNHee Jung Nam
Hee Jung Nam
MLMeerae Lim
Meerae Lim
ECEun-Young Cho
Eun-Young Cho
KHKyung Sue Hong
Kyung Sue Hong
Since the introduction of atypical antipsychotics (AAP), both case reports1-6 and clinical studies7-9 have described the de novo onset of obsessive-compulsive (OC) symptoms during treatment with these drugs. In a previous investigation, we screened 209 clinically stable outpatients with schizophrenia who were receiving AAP and found that 12.4% showed AAP-induced OC symptoms.10

11 October 2011 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
SRSeunghyong Ryu
Seunghyong Ryu
SOSohee Oh
Sohee Oh
ECEun‐Young Cho
Eun‐Young Cho
HNHee Jung Nam
Hee Jung Nam
JYJae Hyun Yoo
Jae Hyun Yoo
KHKyung Sue Hong
Kyung Sue Hong

1 December 2007 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
MLMeerae Lim
Meerae Lim
DPDong Yeon Park
Dong Yeon Park
JKJun Soo Kwon
Jun Soo Kwon
YJYeon Ho Joo
Yeon Ho Joo
KHKyung Sue Hong
Kyung Sue Hong

1 February 2015 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
SRSeunghyong Ryu
Seunghyong Ryu
JYJae Hyun Yoo
Jae Hyun Yoo
JKJoo Hyun Kim
Joo Hyun Kim
JCJi Sun Rn-Bsn Choi
Ji Sun Rn-Bsn Choi
JBJi-Hyun Baek
Ji-Hyun Baek
KHKyung Sue Hong
Kyung Sue Hong
This study investigates the clinical nature, prevalence rates, and associated factors of second-generation antipsychotic (SGA)–related tardive dyskinesia and tardive dystonia. To date, these subjects have not been thoroughly investigated. The subjects were 80 non-elderly schizophrenic patients who received SGAs for more than 1 year without any previous exposure to first-generation antipsychotics. Multiple (≥2) direct assessments of movement symptoms were performed. Hospital records longer than 1 recent year describing any observed tardive movement symptoms were reviewed. A current or history of tardive dyskinesia and/or tardive dystonia associated with SGA was identified in 28 (35%) subjects. These patients were being treated with risperidone (n = 15), amisulpride, olanzapine, aripiprazole, ziprasidone, or clozapine at the time of the onset of the movement symptoms. Tardive dyskinesia was mostly in the orolingual area, and the most frequently observed tardive dystonia was torticollis. The median interval between the first exposure to the SGA and the movement syndrome onset was 15 months for tardive dyskinesia and 43 months for tardive dystonia. A history of acute dystonia was significantly associated with tardive dystonia, and comorbid obsessive-compulsive syndrome was related to both tardive movement syndromes. This study indicates that more clinical attention and research efforts are needed regarding SGA-associated tardive movement syndromes, including a larger-scale prevalence assessment. This study is the first to indicate that a comorbid obsessive-compulsive syndrome might be an associated factor of tardive movement syndrome. The association warrants further investigation.

1 January 2018 in Journal of Affective Disorders
Verified
Journal Article
Closed access
SJSehyun Jeon
Sehyun Jeon
JBJi Hyun Baek
Ji Hyun Baek
SYSo Yung Yang
So Yung Yang
YCYujin Choi
Yujin Choi
SASung Woo Ahn
Sung Woo Ahn
KHKyung Sue Hong
Kyung Sue Hong

9 July 2017 in International Journal of Bipolar Disorders
Verified
Journal Article
Open access
PDF file
SASung Woo Ahn
Sung Woo Ahn
JBJi Hyun Baek
Ji Hyun Baek
SYSo-Yung Yang
So-Yung Yang
YKYongkang Kim
Yongkang Kim
YCYoungah Cho
Youngah Cho
KHKyung Sue Hong
Kyung Sue Hong
The efficacy and utility of long-term prophylactic treatment in patients with bipolar disorders (BDs) have not been fully explored. This study aims to estimate the long-term clinical response of patients with BDs to mood stabilizer treatment and to identify the clinical factors associated with that response. The study subjects consisted of 80 patients with bipolar I or bipolar II disorder who had been receiving treatment with lithium and/or valproate for more than 2 years at a single bipolar disorder clinic. The long-term response to the best treatment option based on treatment algorithms was evaluated using the Alda scale. Clinical characteristics were evaluated on a lifetime basis. Patients were classified into two response groups based on frequentist mixture analysis using the total Alda scale score. Thirty-four percent of the patients were good responders, with a total Alda score of 5 or higher. The treatment response rate did not differ between the lithium and valproate groups, but lithium and valproate combination therapy was associated with poorer response. The number of previous mixed episodes was associated with a worse response (p = 0.026). Of individual symptoms, delusions during manic episodes (p = 0.008) and increased appetite (p = 0.035) during depressive episodes were more common in moderate/poor responders than in good responders. Co-morbid anxiety disorders were more frequently observed in the moderate/poor response group (p = 0.008). Psychotic, mixed, and atypical features of BDs were found to be correlated with long-term treatment outcomes. Lithium and valproate showed similar efficacy but moderate/poor responders preferred to use polypharmacy.